



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: Box ISSUE FEE  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SCULLY, SCOTT, MURPHY & PRESSER  
200 GARDEN CITY PLAZA  
GARDEN CITY, NY 11530-3391

**NOTICE OF ALLOWANCE  
AND ISSUE FEE DUE**

Note attached communication from the Examiner  
 This notice is issued in view of applicant's communication filed \_\_\_\_\_

SERIES CODE/SERIAL NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
07/042,498	04/24/87	009	HOFFER, F	102 11/20/89
First Named Applicant	O'BRIEN,		TIMOTHY J.	
TITLE OF INVENTION	TUMOR SPECIFIC ASSAY FOR CA125 OVARIAN CANCER ANTIGEN			

	ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. TYPE	SMALL ENTITY	FEES DUE	DATE DUE
1	6626	435-007.000	A82	UTILITY	NO	\$620.00	02/20/90

**THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.  
PROSECUTION ON THE MERITS IS CLOSED.**

**THE ISSUE FEE MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS  
APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED.**

**HOW TO RESPOND TO THIS NOTICE:**

I. Review the SMALL ENTITY Status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the Status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
- B. If the Status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO:

- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.

II. Part B of this notice should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by a charge to deposit account, Part B should be completed and returned. If you are charging the ISSUE FEE to your deposit account, Part C of this notice should also be completed and returned.

III. All communications regarding this application must give series code (or filing date), serial number and batch number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

***IMPORTANT REMINDER: Patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees.***



## UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

## EXAMINER

ART UNIT	PAPER NUMBER
170	

DATE MAILED:

*Subj*  
11/17/89

## NOTICE OF ALLOWABILITY

## PART I.

1.  This communication is responsive to Supplemental Amendment and Declaration of 10/25/89.
2.  All the claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice Of Allowance And Issue Fee Due or other appropriate communication will be sent in due course.
3.  The allowed claims are 1 and 3-10.
4.  The drawings filed on \_\_\_\_\_ are acceptable.
5.  Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has [ ] been received. [ ] not been received. [ ] been filed in parent application Serial No. \_\_\_\_\_, filed on \_\_\_\_\_.
6.  Note the attached Examiner's Amendment.
7.  Note the attached Examiner Interview Summary Record, PTOL-413.
8.  Note the attached Examiner's Statement of Reasons for Allowance.
9.  Note the attached NOTICE OF REFERENCES CITED, PTO-892.
10.  Note the attached INFORMATION DISCLOSURE CITATION, PTO-1449.

## PART II.

A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" indicated on this form. Failure to timely comply will result in the ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

1.  Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
2.  APPLICANT MUST MAKE THE DRAWING CHANGES INDICATED BELOW IN THE MANNER SET FORTH ON THE REVERSE SIDE OF THIS PAPER.
  - a.  Drawing informalities are indicated on the NOTICE RE PATENT DRAWINGS, PTO-948, attached hereto or to Paper No. \_\_\_\_\_. CORRECTION IS REQUIRED.
  - b.  The proposed drawing correction filed on \_\_\_\_\_ has been approved by the examiner. CORRECTION IS REQUIRED.
  - c.  Approved drawing corrections are described by the examiner in the attached EXAMINER'S AMENDMENT. CORRECTION IS REQUIRED.
  - d.  Formal drawings are now REQUIRED.

Any response to this letter should include in the upper right hand corner, the following information from the NOTICE OF ALLOWANCE AND ISSUE FEE DUE: ISSUE BATCH NUMBER, DATE OF THE NOTICE OF ALLOWANCE, AND SERIAL NUMBER.

## Attachments:

- Examiner's Amendment
- Examiner Interview Summary Record, PTOL- 413
- Reasons for Allowance
- Notice of References Cited, PTO-892
- Information Disclosure Citation, PTO-1449
- Notice of Informal Application, PTO-152
- Notice re Patent Drawings, PTO-948
- Listing of Bonded Draftsmen
- Other

DAVID M. NAFF  
PRIMARY EXAMINER  
ART UNIT 182

SN: 07/642498  
7811

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Mr. Frank DiGilio on November 16, 1989.

The examiner makes the following changes:

- a). in claim 1, line 2, insert --serous cystadinocarcinoma-- after "of";  
also on line 2, delete "CA 125" and insert --CA125-- after "antigen"; ✓
- b). in claim 3, line 2, insert --molecular weight-- after "dalton", delete  
"the" and insert --serous cystadinocarcinoma-- before the term "ovarian";
- c). in claim 5, delete lines 1-5, and insert --A method of detection of  
ovarian cancer which comprises the steps of contacting the serum of an  
individual suspected of having the cancer with at least one antibody having  
specificity for a 40 kilodalton subunit of serous cystadinocarcinoma ovarian  
tumor associated antigen CA125 and detecting a subunit-antibody reaction.--
- d). in claim 6, line 5, insert --molecular weight-- after "kilodalton",  
delete "ovarian tumor associated", insert --the-- after "of" and insert --  
antigen-- after "CA125";
- e). in claim 6, line 6, insert --the-- after "for";
- f). in claim 6, line 10, delete "ovarian tumor associated" and insert --  
the-- after the second occurrence of "for";

g). in claim 7, line 2 delete "being compartmentalized to receive" and insert --containing--;

h). in claim 7, line 4, insert --molecular weight-- after "kilodalton" and insert --serous cystadinocarcinoma-- before the term "ovarian";

D3  
i). in claim 7, line 6, insert --serous cystadinocarcinoma-- before the term "ovarian";


j). in claim 10, line 3, delete the second occurrence of "container".

In the abstract, at page 26, line 3, insert --serous cystadinocarcinoma ovarian tumor associated antigen-- after "of" and delete "antigen".

An inquiry concerning this communication should be directed to Florina B. Hoffer at telephone number (703) 557-9173.

FBHOFFER

11/16/1989



DAVID M. NAFF  
PRIMARY EXAMINER  
ART UNIT 182